S40 Pathophysiologic Consequences of Aberrant Heterotrimeric G Protein Regulation

Program: Symposia
Basic/Translational Session
Saturday, April 2, 2016: 4:45 PM-6:15 PM
Room 160 (BCEC)
Peter A. Friedman, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA

Nothing to Disclose: PAF
4:45 PM
Lee S. Weinstein, MD, Metabolic Diseases Branch, NIDDK, NIH, Bethesda, MD
Nothing to Disclose: LSW
5:15 PM
Yingzi Yang, PhD, Developmental Biology, Harvard School of Dental Medicine, Boston, MA
Nothing to Disclose: YY
5:45 PM
Mikel Garcia-Marcos, PhD, Biochemistry, Boston University, Boston, MA
Nothing to Disclose: MG
See more of: Symposia


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire